A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2018
At a glance
- Drugs MGA 012 (Primary) ; MGD 009 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MacroGenics
- 25 Jan 2018 New trial record
- 24 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
- 24 Jan 2018 Status changed from not yet recruiting to recruiting.